ABOUT BIOREGULATION
The immune system acts to protect the body from foreign agents, including bacteria and viruses.
A normally functioning immune system carries out a complex set of interactions that result in the destruction of invading agents. An important aspect of this process is the ability to recognize self from non-self. Autoimmune diseases such as idiopathic thrombocytopenic purpura, rheumatoid arthritis and others, result when this self-recognition goes awry and the immune system mistakenly identifies self tissues as being foreign. In rheumatoid arthritis, the dysregulation of the immune system causes the joint lining to form invasive tissue that leads to degradation of cartilage and bone. Current treatments for rheumatoid arthritis require indefinite drug therapy. Moreover, the vast majority of today’s FDA approved therapies for the treatment of rheumatoid arthritis carry significant side effects, such as potential infections and even the possible development of cancer. These drugs generally target specific products of the immune response that are formed well after the immune system has lost its ability to self-regulate.
Protalex believes that its bioregulatory compound, PRTX-100, has the potential to restore normal immune response by targeting the disease at its source. PRTX-100 has been shown to have minimal side effects at treatment dosages in animal studies. Studies performed reveal that PRTX-100 exerts its effects very early in the immune response to prevent the activation of immune cells and the secretion of pathogenic cytokines. In the animal model specifically designed to evaluate the efficacy of anti-arthritic drugs, PRTX-100 inhibited the development of inflammation.